Ksenija Gorni

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 10

Top Topics

Autism Spectrum Disorder

Children With Cerebral Palsy

Duchenne Muscular Dystrophy

Top Venues

Journal of neurology

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Maria Jędrzejowska, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Renata S Scalco, Paulo Fontoura, Francesco Muntoni, null null
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Journal of neurology (2024)
Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Maria Jędrzejowska, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Renata S Scalco, Paulo Fontoura, Francesco Muntoni, null null
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Journal of neurology 271 (8) (2024)
Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Maria Jędrzejowska, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Renata S Scalco, Paulo Fontoura, Francesco Muntoni, null null
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Journal of neurology 271 (8) (2024)
Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Maria Jędrzejowska, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Renata S Scalco, Paulo Fontoura, Francesco Muntoni, null null
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Journal of neurology 271 (8) (2024)
Claudia A Chiriboga, Claudio Bruno, Tina Duong, Dirk Fischer, Eugenio Mercuri, Janbernd Kirschner, Maria Jędrzejowska, Birgit Jaber, Ksenija Gorni, Heidemarie Kletzl, Imogen Carruthers, Carmen Martin, Renata S Scalco, Paulo Fontoura, Francesco Muntoni, null null
JEWELFISH: 24-month results from an open-label study in non-treatment-naïve patients with SMA receiving treatment with risdiplam. Journal of neurology 271 (8) (2024)
Maryam Oskoui, John W Day, Nicolas Deconinck, Elena Stacy Mazzone, Andres Nascimento, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Nathalie M Goemans, Janbernd Kirschner, Maria Jędrzejowska, Laurent Servais, Gergely Papp, Ksenija Gorni, Heidemarie Kletzl, Carmen Martin, Tammy McIver, Renata S Scalco, Hannah Staunton, Wai Yin Yeung, Paulo Fontoura, Eugenio Mercuri, null null
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). Journal of neurology (2023)
Valerie Aponte Ribero, Yasmina Martí, Sarah Batson, Stephen Mitchell, Ksenija Gorni, Nicole Gusset, Maryam Oskoui, Laurent Servais, C Simone Sutherland
Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures. Neurology (2023)
Maryam Oskoui, John W Day, Nicolas Deconinck, Elena Stacy Mazzone, Andres Nascimento, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Nathalie M Goemans, Janbernd Kirschner, Maria Jędrzejowska, Laurent Servais, Gergely Papp, Ksenija Gorni, Heidemarie Kletzl, Carmen Martin, Tammy McIver, Renata S Scalco, Hannah Staunton, Wai Yin Yeung, Paulo Fontoura, Eugenio Mercuri, null null
Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA). Journal of neurology (2023)
Maryam Oskoui, John W Day, Nicolas Deconinck, Elena Stacy Mazzone, Andres Nascimento, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Nathalie M Goemans, Janbernd Kirschner, Maria Jędrzejowska, Laurent Servais, Gergely Papp, Ksenija Gorni, Heidemarie Kletzl, Carmen Martin, Tammy McIver, Renata S Scalco, Hannah Staunton, Wai Yin Yeung, Paulo Fontoura, Eugenio Mercuri, null null
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). Journal of neurology (2023)
Siu Hing Lo, Ksenija Gorni, C Simone Sutherland, Yasmina Martí, Andrew J Lloyd, Noman Paracha
Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom. PharmacoEconomics (2021)